# Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

> **NCT04303169** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 146 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Vibostolimab
- **BIOLOGICAL:** Gebasaxturev
- **BIOLOGICAL:** MK-4830
- **BIOLOGICAL:** Favezelimab + Pembrolizumab
- **DRUG:** ATRA

## Key facts

- **NCT ID:** NCT04303169
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-26
- **Primary completion:** 2025-09-24
- **Final completion:** 2025-09-24
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2025-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04303169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04303169, "Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04303169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*